Profile
Sheng Cui currently works at NewAmsterdam Pharma Co. NV, as Chief Manufacturing Officer from 2023.
Dr. Cui also formerly worked at Amgen, Inc., as Scientific Director from 2018 to 2019 and Boston Pharmaceuticals, Inc., as Head-Chemistry Manufacturing & Controls from 2020 to 2021.
Dr. Cui received his doctorate degree from Case Western Reserve University and undergraduate degree from Nankai University.
Sheng Cui active positions
| Companies | Position | Start |
|---|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Corporate Officer/Principal | 2021-03-31 |
Former positions of Sheng Cui
| Companies | Position | End |
|---|---|---|
Boston Pharmaceuticals, Inc.
Boston Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage biopharmaceutical company that develops therapies for patients | Corporate Officer/Principal | 2021-03-31 |
| AMGEN INC. | Chief Tech/Sci/R&D Officer | 2019-02-28 |
Training of Sheng Cui
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Case Western Reserve University
Case Western Reserve University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nankai University
Nankai University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Boston Pharmaceuticals, Inc.
Boston Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage biopharmaceutical company that develops therapies for patients | Commercial Services |
NewAmsterdam Pharma Co. NV
NewAmsterdam Pharma Co. NV Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that researches, develops, manufactures and commercializes transformative therapies for cardio-metabolic diseases | Health Technology |
- Stock Market
- Insiders
- Sheng Cui
















